Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma - PubMed
3 hours ago
- #Esophageal Squamous Cell Carcinoma
- #Neoadjuvant Therapy
- #Nivolumab
- Nivolumab combined with neoadjuvant chemoradiotherapy (CRT) and esophagectomy was studied for locally advanced esophageal squamous cell carcinoma (ESCC).
- The phase II trial aimed to assess pathological complete response (pCR) as the primary endpoint, with secondary endpoints including feasibility, safety, and survival metrics.
- Out of 17 enrolled patients, 14 underwent esophagectomy, with a pCR rate of 4 patients, not meeting the criteria to proceed to stage II.
- Treatment emergent adverse events (TEAEs) were observed in 15 patients, with 4 experiencing grade 3 or higher events.
- Patients with high PD-L1 expression showed a significantly higher pCR rate (100%) compared to those with low expression (18%).
- The study concluded that the combination therapy is safe and may benefit patients with high PD-L1 expression.